Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture

[1]  E. Barrett-Connor,et al.  Bone mineral density thresholds for pharmacological intervention to prevent fractures. , 2004, Archives of internal medicine.

[2]  O. Johnell,et al.  Associations Between Baseline Risk Factors and Vertebral Fracture Risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  J. Kanis,et al.  Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double‐Blind, Placebo‐Controlled 3‐Year Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  T. Spector,et al.  Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.

[5]  O. Johnell,et al.  Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. , 2003, Bone.

[6]  S. Eichner,et al.  Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment , 2003, The Annals of pharmacotherapy.

[7]  Dieter Felsenberg,et al.  Risedronate prevents new vertebral fractures in postmenopausal women at high risk. , 2003, The Journal of clinical endocrinology and metabolism.

[8]  R. Marcus,et al.  The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  L. Lenchik,et al.  What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis? , 2002, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[10]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[11]  J. Kanis,et al.  Diagnosis of osteoporosis and assessment of fracture risk , 2002, The Lancet.

[12]  J A Kanis,et al.  Assessing the risk of vertebral osteoporosis. , 2002, Singapore medical journal.

[13]  O. Johnell,et al.  Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds , 2001, Osteoporosis International.

[14]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[15]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[16]  T. Abbott,et al.  Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[18]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[19]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[20]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[21]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[22]  J. Compston,et al.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (WHO Technical Report Series No 843) , 1995 .

[23]  J. Kanis,et al.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report , 1994, Osteoporosis International.

[24]  M. Chapuy,et al.  Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women , 1994, BMJ.

[25]  F Duboeuf,et al.  Vitamin D3 and calcium to prevent hip fractures in elderly women. , 1992, The New England journal of medicine.

[26]  Claus Christiansen,et al.  Diagnosis of Osteoporosis , 1992, Southern medical journal.

[27]  H. Kopera,et al.  Briefe an die Redaktion , 1989, Klinische Wochenschrift.

[28]  Everett M. Rogers,et al.  Consensus Development Conference , 1984 .

[29]  S. Cummings,et al.  Design of the Fracture Intervention Trial , 2005, Osteoporosis International.

[30]  Claus Christiansen,et al.  Consensus development conference: Prophylaxis and treatment of osteoporosis , 2005, Osteoporosis International.

[31]  C. Cooper,et al.  Guidelines for diagnosis and management of osteoporosis , 2005, Osteoporosis International.

[32]  R. Goodman,et al.  The effect of risedronate on the risk of hip fracture in elderly women. , 2001, The New England journal of medicine.

[33]  Harry K. Genant,et al.  Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .

[34]  R. Eastell,et al.  The Use of Biochemical Markers of Bone Turnover in Osteoporosis , 2000, Osteoporosis International.

[35]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[36]  J. Kanis,et al.  An Update on the Diagnosis and Assessment of Osteoporosis with Densitometry , 2000, Osteoporosis International.

[37]  H. Wahner,et al.  Updated Data on Proximal Femur Bone Mineral Levels of US Adults , 1998, Osteoporosis International.

[38]  Osteoporosis: Review of the Evidence for Prevention, Diagnosis and Treatment and Cost-Effective Analysis , 1998, Osteoporosis International.

[39]  C. Cooper,et al.  Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. , 1997, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.